Table 2.

Risk of adenoma after randomization in the intention-to-treat population

No. (%) of participants
Folic acid (n = 430)Control (n = 430)RR (95% CI)P
Any adenoma641320.49 (0.37–0.63)<0.001
(14.88%)(30.70%)0.74a (0.65–0.85)
No. of adenomas ≥ 314200.70 (0.36–1.77)0.38
(3.26%)(4.65%)1.01a (0.87–1.16)
Left-sided adenoma42780.54 (0.38–0.76)0.001
(9.77%)(18.14%)0.40a (0.33–0.49)
Right-sided adenoma16290.55 (0.30–1.00)0.07
(3.72%)(6.74%)0.77a (0.55–1.09)
Advanced adenoma8220.36 (0.16–0.81)0.01
(1.86%)(5.17%)0.67a (0.58–0.76)
CRCs221.00 (0.14–7.07)1.00
(0.47%)(0.47%)1.00a (0.87–1.15)

NOTE: The intention-to-treat population comprised all randomized participants with 3 years of follow-up data, including those participants who discontinued. P values are based on the χ2 test.

  • aAdjustment for age, sex, clinical center, and duration of follow-up at baseline.